A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus

A. Crinò, R. Schiaffini, P. Ciampalini, M. C. Suraci, S. Manfrini, N. Visalli, M. C. Matteoli, P. Patera, R. Buzzetti, C. Guglielmi, S. Spera, F. Costanza, E. Fioriti, D. Pitocco, Paolo Pozzilli, S. Corbi, M. Cervoni, M. L. Manca Bitti, C. Bizzarri, A. Lauria PantanoL. Cipolloni, G. Coppolino, L. Valente, G. Beretta Anguissola, A. L. Montemari, M. Cappa, M. Cervoni, E. Di Stasio, L. Nisticò, A. Petrone, M. G. Cavallo, G. Ghirlanda

Research output: Contribution to journalArticle

Abstract

Background and Aims: A number of trials have evaluated residual beta-cell function in patients with recent onset type 1 diabetes mellitus (DM1) treated with nicotinamide in addition to intensive insulin therapy (IIT). In most studies, only a slight decline of C-peptide secretion was observed 12 months after diagnosis; however, no data is available on C-peptide secretion and metabolic control in patients continuing nicotinamide and IIT for up to 2 years after diagnosis. Patients and Methods: We retrospectively analysed data from 25 patients (mean age 14.7 years ± 5 SD) with DM1 in whom nicotinamide at a dose of 25 mg/kg b. wt. was added from diagnosis (1c levels were evaluated at 12 and 24 months after diagnosis. Results: In the course of the follow-up, patients on nicotinamide + IIT or IIT alone did not significantly differ in terms of C-peptide secretion (values at 24 months in the two groups were 0.19 ± 0.24 nM vs 0.19 ± 0.13 nM, respectively). Insulin requirement (0.6 ± 0.3 U/kg/day vs 0.7 ± 0.2 U/kg/day at 24 months, respectively) did not differ between the two groups. However, HbA1c was significantly lower 2 years after diagnosis in patients treated with nicotinamide + IIT (6.09 ± 0.9% vs 6.98 ± 0.9%, respectively, p 1c. In both nicotinamide and control patients, no decline in C-peptide was detected 2 years after diagnosis, indicating that IIT preserves C-peptide secretion. We conclude that nicotinamide + IIT at diagnosis of DM1 prolonged for up to 2 years can be recommended, but longer follow-up is required to determine whether nicotinamide should be continued beyond this period.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number8
Publication statusPublished - Aug 2005

Fingerprint

Niacinamide
Type 1 Diabetes Mellitus
Observational Studies
C-Peptide
Insulin
Therapeutics

Keywords

  • C-peptide
  • Intensive insulin therapy
  • Nicotinamide
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. / Crinò, A.; Schiaffini, R.; Ciampalini, P.; Suraci, M. C.; Manfrini, S.; Visalli, N.; Matteoli, M. C.; Patera, P.; Buzzetti, R.; Guglielmi, C.; Spera, S.; Costanza, F.; Fioriti, E.; Pitocco, D.; Pozzilli, Paolo; Corbi, S.; Cervoni, M.; Manca Bitti, M. L.; Bizzarri, C.; Lauria Pantano, A.; Cipolloni, L.; Coppolino, G.; Valente, L.; Beretta Anguissola, G.; Montemari, A. L.; Cappa, M.; Cervoni, M.; Di Stasio, E.; Nisticò, L.; Petrone, A.; Cavallo, M. G.; Ghirlanda, G.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 18, No. 8, 08.2005, p. 749-754.

Research output: Contribution to journalArticle

Crinò, A, Schiaffini, R, Ciampalini, P, Suraci, MC, Manfrini, S, Visalli, N, Matteoli, MC, Patera, P, Buzzetti, R, Guglielmi, C, Spera, S, Costanza, F, Fioriti, E, Pitocco, D, Pozzilli, P, Corbi, S, Cervoni, M, Manca Bitti, ML, Bizzarri, C, Lauria Pantano, A, Cipolloni, L, Coppolino, G, Valente, L, Beretta Anguissola, G, Montemari, AL, Cappa, M, Cervoni, M, Di Stasio, E, Nisticò, L, Petrone, A, Cavallo, MG & Ghirlanda, G 2005, 'A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus', Journal of Pediatric Endocrinology and Metabolism, vol. 18, no. 8, pp. 749-754.
Crinò, A. ; Schiaffini, R. ; Ciampalini, P. ; Suraci, M. C. ; Manfrini, S. ; Visalli, N. ; Matteoli, M. C. ; Patera, P. ; Buzzetti, R. ; Guglielmi, C. ; Spera, S. ; Costanza, F. ; Fioriti, E. ; Pitocco, D. ; Pozzilli, Paolo ; Corbi, S. ; Cervoni, M. ; Manca Bitti, M. L. ; Bizzarri, C. ; Lauria Pantano, A. ; Cipolloni, L. ; Coppolino, G. ; Valente, L. ; Beretta Anguissola, G. ; Montemari, A. L. ; Cappa, M. ; Cervoni, M. ; Di Stasio, E. ; Nisticò, L. ; Petrone, A. ; Cavallo, M. G. ; Ghirlanda, G. / A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. In: Journal of Pediatric Endocrinology and Metabolism. 2005 ; Vol. 18, No. 8. pp. 749-754.
@article{6891a544363d4065a8ff07673740854d,
title = "A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus",
abstract = "Background and Aims: A number of trials have evaluated residual beta-cell function in patients with recent onset type 1 diabetes mellitus (DM1) treated with nicotinamide in addition to intensive insulin therapy (IIT). In most studies, only a slight decline of C-peptide secretion was observed 12 months after diagnosis; however, no data is available on C-peptide secretion and metabolic control in patients continuing nicotinamide and IIT for up to 2 years after diagnosis. Patients and Methods: We retrospectively analysed data from 25 patients (mean age 14.7 years ± 5 SD) with DM1 in whom nicotinamide at a dose of 25 mg/kg b. wt. was added from diagnosis (1c levels were evaluated at 12 and 24 months after diagnosis. Results: In the course of the follow-up, patients on nicotinamide + IIT or IIT alone did not significantly differ in terms of C-peptide secretion (values at 24 months in the two groups were 0.19 ± 0.24 nM vs 0.19 ± 0.13 nM, respectively). Insulin requirement (0.6 ± 0.3 U/kg/day vs 0.7 ± 0.2 U/kg/day at 24 months, respectively) did not differ between the two groups. However, HbA1c was significantly lower 2 years after diagnosis in patients treated with nicotinamide + IIT (6.09 ± 0.9{\%} vs 6.98 ± 0.9{\%}, respectively, p 1c. In both nicotinamide and control patients, no decline in C-peptide was detected 2 years after diagnosis, indicating that IIT preserves C-peptide secretion. We conclude that nicotinamide + IIT at diagnosis of DM1 prolonged for up to 2 years can be recommended, but longer follow-up is required to determine whether nicotinamide should be continued beyond this period.",
keywords = "C-peptide, Intensive insulin therapy, Nicotinamide, Type 1 diabetes mellitus",
author = "A. Crin{\`o} and R. Schiaffini and P. Ciampalini and Suraci, {M. C.} and S. Manfrini and N. Visalli and Matteoli, {M. C.} and P. Patera and R. Buzzetti and C. Guglielmi and S. Spera and F. Costanza and E. Fioriti and D. Pitocco and Paolo Pozzilli and S. Corbi and M. Cervoni and {Manca Bitti}, {M. L.} and C. Bizzarri and {Lauria Pantano}, A. and L. Cipolloni and G. Coppolino and L. Valente and {Beretta Anguissola}, G. and Montemari, {A. L.} and M. Cappa and M. Cervoni and {Di Stasio}, E. and L. Nistic{\`o} and A. Petrone and Cavallo, {M. G.} and G. Ghirlanda",
year = "2005",
month = "8",
language = "English",
volume = "18",
pages = "749--754",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

TY - JOUR

T1 - A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus

AU - Crinò, A.

AU - Schiaffini, R.

AU - Ciampalini, P.

AU - Suraci, M. C.

AU - Manfrini, S.

AU - Visalli, N.

AU - Matteoli, M. C.

AU - Patera, P.

AU - Buzzetti, R.

AU - Guglielmi, C.

AU - Spera, S.

AU - Costanza, F.

AU - Fioriti, E.

AU - Pitocco, D.

AU - Pozzilli, Paolo

AU - Corbi, S.

AU - Cervoni, M.

AU - Manca Bitti, M. L.

AU - Bizzarri, C.

AU - Lauria Pantano, A.

AU - Cipolloni, L.

AU - Coppolino, G.

AU - Valente, L.

AU - Beretta Anguissola, G.

AU - Montemari, A. L.

AU - Cappa, M.

AU - Cervoni, M.

AU - Di Stasio, E.

AU - Nisticò, L.

AU - Petrone, A.

AU - Cavallo, M. G.

AU - Ghirlanda, G.

PY - 2005/8

Y1 - 2005/8

N2 - Background and Aims: A number of trials have evaluated residual beta-cell function in patients with recent onset type 1 diabetes mellitus (DM1) treated with nicotinamide in addition to intensive insulin therapy (IIT). In most studies, only a slight decline of C-peptide secretion was observed 12 months after diagnosis; however, no data is available on C-peptide secretion and metabolic control in patients continuing nicotinamide and IIT for up to 2 years after diagnosis. Patients and Methods: We retrospectively analysed data from 25 patients (mean age 14.7 years ± 5 SD) with DM1 in whom nicotinamide at a dose of 25 mg/kg b. wt. was added from diagnosis (1c levels were evaluated at 12 and 24 months after diagnosis. Results: In the course of the follow-up, patients on nicotinamide + IIT or IIT alone did not significantly differ in terms of C-peptide secretion (values at 24 months in the two groups were 0.19 ± 0.24 nM vs 0.19 ± 0.13 nM, respectively). Insulin requirement (0.6 ± 0.3 U/kg/day vs 0.7 ± 0.2 U/kg/day at 24 months, respectively) did not differ between the two groups. However, HbA1c was significantly lower 2 years after diagnosis in patients treated with nicotinamide + IIT (6.09 ± 0.9% vs 6.98 ± 0.9%, respectively, p 1c. In both nicotinamide and control patients, no decline in C-peptide was detected 2 years after diagnosis, indicating that IIT preserves C-peptide secretion. We conclude that nicotinamide + IIT at diagnosis of DM1 prolonged for up to 2 years can be recommended, but longer follow-up is required to determine whether nicotinamide should be continued beyond this period.

AB - Background and Aims: A number of trials have evaluated residual beta-cell function in patients with recent onset type 1 diabetes mellitus (DM1) treated with nicotinamide in addition to intensive insulin therapy (IIT). In most studies, only a slight decline of C-peptide secretion was observed 12 months after diagnosis; however, no data is available on C-peptide secretion and metabolic control in patients continuing nicotinamide and IIT for up to 2 years after diagnosis. Patients and Methods: We retrospectively analysed data from 25 patients (mean age 14.7 years ± 5 SD) with DM1 in whom nicotinamide at a dose of 25 mg/kg b. wt. was added from diagnosis (1c levels were evaluated at 12 and 24 months after diagnosis. Results: In the course of the follow-up, patients on nicotinamide + IIT or IIT alone did not significantly differ in terms of C-peptide secretion (values at 24 months in the two groups were 0.19 ± 0.24 nM vs 0.19 ± 0.13 nM, respectively). Insulin requirement (0.6 ± 0.3 U/kg/day vs 0.7 ± 0.2 U/kg/day at 24 months, respectively) did not differ between the two groups. However, HbA1c was significantly lower 2 years after diagnosis in patients treated with nicotinamide + IIT (6.09 ± 0.9% vs 6.98 ± 0.9%, respectively, p 1c. In both nicotinamide and control patients, no decline in C-peptide was detected 2 years after diagnosis, indicating that IIT preserves C-peptide secretion. We conclude that nicotinamide + IIT at diagnosis of DM1 prolonged for up to 2 years can be recommended, but longer follow-up is required to determine whether nicotinamide should be continued beyond this period.

KW - C-peptide

KW - Intensive insulin therapy

KW - Nicotinamide

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=24944438390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944438390&partnerID=8YFLogxK

M3 - Article

C2 - 16200840

AN - SCOPUS:24944438390

VL - 18

SP - 749

EP - 754

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 8

ER -